Merck's Phase II trial of grazoprevir/elbasvir in hepatitis C genotype 1 positive

12 November 2014

Pharma giant Merck & Co (NYSE: MRK) has presented results from its Phase II trial of grazoprevir/elbasvir, with or without ribavirin in treatment-naive and previously-treated with peginterferon/ribavirin patients with chronic hepatitis C genotype 1 infection.

The rates of sustained viral response 12 weeks after the completion of therapy in treatment-naive cirrhotic patients were 90% in the grazoprevir/elbasvir and ribavirin combination arm, and 97% in the arm without ribavirin. This stood at 97% in combination with ribavirin and 94% without at 18 weeks.

The grazoprevir/elbasvir and peginterferon/ribavirin combination patients with or without cirrhosis achieved sustained viral response rates of 94% at 12 weeks with ribavirin and 91% without, rising to 100% at 18 weeks with ribavirin and 97% without.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK